Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on ESPR. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC cut their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Esperion Therapeutics Stock Performance

ESPR opened at $2.41 on Tuesday. The stock has a market capitalization of $474.87 million, a price-to-earnings ratio of -3.63 and a beta of 0.96. The company has a fifty day moving average of $1.99 and a 200 day moving average of $2.14. Esperion Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $3.40.

Institutional Trading of Esperion Therapeutics

Several hedge funds have recently made changes to their positions in ESPR. Barclays PLC increased its stake in Esperion Therapeutics by 99.6% during the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 154,509 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics during the 3rd quarter valued at $606,000. Anson Funds Management LP purchased a new stake in Esperion Therapeutics during the 3rd quarter valued at $540,000. Finally, Wellington Management Group LLP lifted its position in Esperion Therapeutics by 66.8% in the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after buying an additional 241,512 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.